We are pleased to see more progress in the Actos bladder cancer litigation. Our Firm continues to receive regular inquiries from Actos users who may have developed bladder cancer due to their use of this medication.
New York, New York (PRWEB) May 29, 2013
Hundreds of Actos lawsuit claims continue to progress in the Actos bladder cancer litigation now underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court records, a Status Conference was convened in the Actos litigation on May 23rd. Issues addressed included the status of federal and state court Actos lawsuits, the status of discovery, and the litigation’s bellwether trials. The Court also scheduled the proceeding’s next Status Conference for June 20, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)
“We are pleased to see more progress in the Actos bladder cancer litigation. Our Firm continues to receive regular inquiries from Actos users who may have developed bladder cancer due to their use of this medication,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm's Actos lawyers are currently offering free legal evaluations to alleged victims of Actos bladder cancer.
Court documents indicate that at least 1,200 Actos bladder cancer lawsuits are pending in the Western District of Louisiana. The litigation’s first bellwether trials are scheduled to begin in January. All of the Actos lawsuits filed in the proceeding allege Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer.
According to a May 1st Bloomberg.com report, additional Actos bladder cancer claims have been filed in state litigations in California and Illinois.* Last month, the Los Angeles Superior Court jury hearing the nation’s first Actos trial ruled in favor of the Plaintiff, awarding $6.5 million to a man who was diagnosed with the disease after taking the medication for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Actos is used to control blood-sugar levels in type 2 diabetes patients. In June 2011, the U.S. Food & Drug Administration (FDA) warned that long-term use of the drug could increase the chances of developing bladder cancer, prompting hundreds of people to file Actos lawsuits.** The same month the FDA issued its Actos bladder cancer warning, sales of the drug were suspended in Germany and France due to its association with the disease.***
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact one of the Firm’s Actos lawyers by calling 800-511-5092 today.
**FDA, June 15, 2011; fda.gov/drugs/drugsafety/ucm259150.htm
***Bloomberg, December 31, 2011; bloomberg.com/news/2011-12-31/takeda-suits-on-actos-diabetes-drug-combined-in-one-louisiana-court.html
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP